MilleGen Pharma division has established a Therapeutic Antibody Pipeline for cancer treatment using innovative technologies. MilleGen proprietary protein engineering technologies allow to develop better biotherapeutics.
Fully human monoclonal antibodies are selected from an optimized quality library (MG-Umab library) to develop targeted therapies.
Our genetic antibody maturation technology allows antibody binding maturation to its target as well as Fc engineering. Our expertise permits us to propose customized Fc that can be adapted to any therapeutic antibody and Fc-fusion protein. MilleGen is developing the third generation of therapeutic antibodies, more potent, safer and longer lasting, to improve clinical outcomes and quality of life of patients.
MilleGen SERVICES: DNA Sequencing, Molecular Biology and Peptide Synthesis
MilleGen provides 12 years of experience and expertise in biotechnology services including High-Throughput DNA Sequencing, Molecular Biology projects, Bioinformatics, Peptides Synthesis and Antibodies Sequencing.